USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Core Insights - IGC Pharma, Inc. has been granted U.S. Patent No. 12,465,589 for methods and compositions aimed at treating CNS disorders, specifically targeting Alzheimer's disease [1] Company Summary - IGC Pharma is a clinical-stage biotechnology company focused on leveraging Artificial Intelligence to develop innovative treatments for Alzheimer's disease [1] - The patent granted by the USPTO signifies a significant milestone for the company in its research and development efforts [1]